Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in CRSP.

← Back to Free Index

CRSP

Analysis as of: 2026-07-14

CRISPR Therapeutics AG

CRISPR Therapeutics develops gene-based medicines using CRISPR/Cas9, SyNTase, siRNA, and cell therapy platforms, with CASGEVY as its first approved product.

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved Anchor, Platform Proof Still Pending

The approved launch gives the story a real floor, but most of the upside still depends on showing another scalable human proof point. One owned franchise win can rerate the business; a string of misses leaves it as a narrow, partner-mediated asset.

Analysis

Thesis

CRISPR Therapeutics already has real regulatory and early commercial proof; if CASGEVY keeps compounding and just one owned franchise in liver editing, autoimmune cell therapy, or siRNA shows durable human proof, the company can rerate from cash-backed science to a multi-asset gene-editing platform by 2031.

Last Economy Alignment

AI should make edit design, assay learning, and process optimization cheaper, while value capture remains anchored in regulated data, IP, and GMP execution; the main cap is still clinical and delivery bottlenecks, not software commoditization.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.8x (from 5 most recent analyses)

Reasoning

The upside does not require every branch to work. A steadier CASGEVY ramp plus one clearly validated owned program in liver editing, autoimmune cell therapy, or siRNA would move the story from balance-sheet support to repeatable franchise value. The pediatric label expansion raises the floor, but the rerating still depends on human proof outside hemoglobinopathies.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is proof conversion, not near-term liquidity. CRISPR needs CASGEVY to become a repeatable economic engine and at least one owned program to show durable, scalable human efficacy; otherwise the company remains dependent on a partner-led hemoglobinopathy asset, periodic financing windows, and a pipeline the market values only as scientific optionality.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On July 1, 2026, FDA expanded CASGEVY in the U.S. to patients aged 2 years and older, increasing the commercial floor and broadening pediatric credibility.
Vertex said the expanded label adds about 5,500 additional U.S. children, which helps the long-duration treatment backlog even if near-term throughput stays constrained.
No new July company disclosure has yet confirmed CTX460 trial initiation, so the next upside gate remains open but un-cleared.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.38

It owns gene-editing know-how, manufacturing, and regulatory learning that AI can make more productive, so cheaper cognition should help rather than hurt. But value still has to pass through hard clinical, manufacturing, and approval gates, which keeps the score positive rather than elite.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$83.52

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research